TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas
Neuro-Oncology · 03.05.2024 · 26 (5) · 811-825
DOI: 10.1093/neuonc/noad214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 06.11.2023. Verfasst von Jiaying Zheng und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Receptors, Immunologic, Membrane Glycoproteins, CD4-Positive T-Lymphocytes, Glioma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NINDS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Background
Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM) and have been implicated in promoting tumor progression and immunosuppression. Modulating the response of myeloid cells to the tumor has emerged as a promising new approach for cancer treatment. In this regard, we focus on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which has recently emerged as a novel immune modulator in peripheral tumors.
Methods
We studied the TREM2 expression profile in various patient tumor samples and conducted single-cell transcriptomic analysis in both GBM patients and the GL261 mouse glioma model. We utilized multiple mouse glioma models and employed state-of-the-art techniques such as invivo 2-photon imaging, spectrum flow cytometry, and in vitro co-culture assays to study TREM2 function in myeloid cell-mediated phagocytosis of tumor cells, antigen presentation, and response of CD4+ T cells within the tumor hemispheres.
Results
Our research revealed significantly elevated levels of TREM2 expression in brain tumors compared to other types of tumors in patients. TREM2 was predominantly localized in tumor-associated myeloid cells and was highly expressed in nearly all microglia, as well as various subtypes of macrophages. Surprisingly, in preclinical glioma models, TREM2 deficiency did not confer a beneficial effect; instead, it accelerated glioma progression. Through detailed investigations, we determined that TREM2 deficiency impaired the ability of tumor-myeloid cells to phagocytose tumor cells and led to reduced expression of MHCII. This deficiency further significantly decreased the presence of CD4+ T cells within the tumor hemispheres.
Conclusions
Our study unveiled a previously unrecognized protective role of tumor-myeloid TREM2. Specifically, we found that TREM2 enhances the phagocytosis of tumor cells and promotes an immune response by facilitating MHCII-associated CD4+ T-cell responses against gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA.
- Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neurologic Surgery, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
ORCID-Profile: Katayoun Ayasoufi, Long-Jun Wu
Förderung
- NIH HHS
- NINDS NIH HHS
- NCI NIH HHS
- National Institutes of Health
- Mayo Clinic Cancer Center
- Mayo Clinic Center for Biomedical Discovery
Zitieren
APA
Zheng, J., Wang, L., Zhao, S., Zhang, W., Chang, Y., Bosco, D. B., Huang, T., Dheer, A., Gao, S., Xu, S., Ayasoufi, K., Al-Kharboosh, R., Qi, F., Xie, M., Johnson, A. J., Dong, H., Quiñones-Hinojosa, A., & Wu, L. J. (2024). TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas. Neuro-Oncology, 26(5), 811-825. https://doi.org/10.1093/neuonc/noad214
Vancouver
Zheng J, Wang L, Zhao S, Zhang W, Chang Y, Bosco DB, et al. TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas. Neuro-Oncology. 2024;26(5):811-825. doi:10.1093/neuonc/noad214
BibTeX
@article{Zheng2024,
author = {Zheng, Jiaying and Wang, Lingxiao and Zhao, Shunyi and Zhang, Wenjing and Chang, Yuzhou and Bosco, Dale B and Huang, Tao and Dheer, Aastha and Gao, Shan and Xu, Shengze and Ayasoufi, Katayoun and Al-Kharboosh, Rawan and Qi, Fangfang and Xie, Manling and Johnson, Aaron J and Dong, Haidong and Quiñones-Hinojosa, Alfredo and Wu, Long-Jun},
title = {TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {5},
pages = {811--825},
doi = {10.1093/neuonc/noad214}
}
EUVIMED